// App-Quantinova.ai

3785 : Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update

Researchers

Presenter

  • Carlo Gambacorti-Passerini

Principal Investigators

  • Hagop M. Kantarjian

  • Virginia Kelly

  • Kathleen Turnbull

  • Nadine Besson

  • Jorge E Cortes

  • Dong-Wook Kim

  • David Marin

  • Pedro E Dorlhiac-Llacer

  • Andrey Zaritskey

  • Juan Navarro

  • Eduardo O Bullorsky

  • Sarit Assouline

  • Eric Leip

Medical Centers

  • Hospital Durand, Buenos Aires, Argentina

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Hammersmith Hospital, Imperial College, London, United Kingdom

  • University of Pavlov, St. Petersburg, Russia

  • Montreal University, Montreal, QC, Canada

  • Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru

  • Hospital Das Clinicas Da FMUSP, Sao Paulo, Brazil

  • University of Milano-Bicocca, Monza, Italy

Locations

  • Brazil

  • Canada

  • Argentina

  • Italy

  • United Kingdom

  • United States

  • Peru

  • Russia

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Gastrointestinal bleeding

  • Chronic Myelogenous Leukemia

  • Thrombocytopenia

  • Neutropenia

  • Lymphocytopenia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Bosutinib

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved